Inhibiting the hypoxia response for cancer therapy: the new kid on the block.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 19789327.
- Also identified by DOI 10.1158/1078-0432.CCR-09-1650 and PMC identifier 2760048.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The hypoxia-inducible transcription factor (HIF)-1alpha inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here, we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with other promising HIF-1alpha inhibitors.
Medical subject headings
- Antineoplastic Agents
- Drug Delivery Systems
- Hypoxia-Inducible Factor 1, alpha Subunit
- Neoplasms